Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption

Carlos L. J. Vrins; Florence Bietrix; Elisa Lombardo; Cindy P. A. A. van Roomen; Roelof Ottenhoff; Herman S. Overkleeft; Johannes M. Aerts

doi:https://doi.org/10.2217/CLP.12.14

Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption

Carlos L. J. Vrins, Florence Bietrix, Elisa Lombardo, Cindy P. A. A. van Roomen, Roelof Ottenhoff, Herman S. Overkleeft, Johannes M. Aerts

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Inhibition of glycosphingolipid synthesis with iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) increases fecal neutral sterol output in mice. To investigate which pathways were involved in this increase, C57BI/6J mice were treated with AMP-DNM and/or ezetimibe. Fecal neutral sterol output increased by threefold with combined AMP-DNM/ezetimibe treatment compared with approximately twofold increases with single treatments. Bile canulations and intestine perfusions showed that biliary cholesterol secretion and transintestinal cholesterol efflux were increased in mice receiving AMP-DNM treatment. This study indicates that AMP-DNM treatment of mice increases fecal neutral sterol by promoting biliary and intestinal cholesterol secretion without inhibiting cholesterol absorption

Original language	English
Pages (from-to)	241-248
Journal	Clinical lipidology
Volume	7
Issue number	2
DOIs	https://doi.org/10.2217/CLP.12.14
Publication status	Published - 2012

Access to Document

https://doi.org/10.2217/CLP.12.14

Cite this

@article{623516eac40e4202bea2d7851a68c79c,

title = "Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption",

abstract = "Inhibition of glycosphingolipid synthesis with iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) increases fecal neutral sterol output in mice. To investigate which pathways were involved in this increase, C57BI/6J mice were treated with AMP-DNM and/or ezetimibe. Fecal neutral sterol output increased by threefold with combined AMP-DNM/ezetimibe treatment compared with approximately twofold increases with single treatments. Bile canulations and intestine perfusions showed that biliary cholesterol secretion and transintestinal cholesterol efflux were increased in mice receiving AMP-DNM treatment. This study indicates that AMP-DNM treatment of mice increases fecal neutral sterol by promoting biliary and intestinal cholesterol secretion without inhibiting cholesterol absorption",

author = "Vrins, {Carlos L. J.} and Florence Bietrix and Elisa Lombardo and {van Roomen}, {Cindy P. A. A.} and Roelof Ottenhoff and Overkleeft, {Herman S.} and Aerts, {Johannes M.}",

year = "2012",

doi = "https://doi.org/10.2217/CLP.12.14",

language = "English",

volume = "7",

pages = "241--248",

journal = "Clinical lipidology",

issn = "1758-4302",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption

AU - Vrins, Carlos L. J.

AU - Bietrix, Florence

AU - Lombardo, Elisa

AU - van Roomen, Cindy P. A. A.

AU - Ottenhoff, Roelof

AU - Overkleeft, Herman S.

AU - Aerts, Johannes M.

PY - 2012

Y1 - 2012

N2 - Inhibition of glycosphingolipid synthesis with iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) increases fecal neutral sterol output in mice. To investigate which pathways were involved in this increase, C57BI/6J mice were treated with AMP-DNM and/or ezetimibe. Fecal neutral sterol output increased by threefold with combined AMP-DNM/ezetimibe treatment compared with approximately twofold increases with single treatments. Bile canulations and intestine perfusions showed that biliary cholesterol secretion and transintestinal cholesterol efflux were increased in mice receiving AMP-DNM treatment. This study indicates that AMP-DNM treatment of mice increases fecal neutral sterol by promoting biliary and intestinal cholesterol secretion without inhibiting cholesterol absorption

AB - Inhibition of glycosphingolipid synthesis with iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) increases fecal neutral sterol output in mice. To investigate which pathways were involved in this increase, C57BI/6J mice were treated with AMP-DNM and/or ezetimibe. Fecal neutral sterol output increased by threefold with combined AMP-DNM/ezetimibe treatment compared with approximately twofold increases with single treatments. Bile canulations and intestine perfusions showed that biliary cholesterol secretion and transintestinal cholesterol efflux were increased in mice receiving AMP-DNM treatment. This study indicates that AMP-DNM treatment of mice increases fecal neutral sterol by promoting biliary and intestinal cholesterol secretion without inhibiting cholesterol absorption

U2 - https://doi.org/10.2217/CLP.12.14

DO - https://doi.org/10.2217/CLP.12.14

M3 - Article

SN - 1758-4302

VL - 7

SP - 241

EP - 248

JO - Clinical lipidology

JF - Clinical lipidology

IS - 2

ER -